|Brand name(s), other common name(s)||Iclusig®|
|Drug type||Tyrosine kinase inhibitor|
|How the drug is given||By mouth|
Ponatinib is FDA approved to treat adult patients who have T315I-positive chronic myeloid leukemia (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia, and chronic phase, accelerated phase, or blast phase chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia for whom no other tyrosine-kinase inhibitor therapy is indicated.
Side effects needing medical attention:Hypertension; rash; abdominal pain; fatigue; dizziness; headache; cough; dry skin; constipation; joint pain; nausea; diarrhea; vomiting; fever; low platelets; low red blood cells; low neutrophils; low level of lymphocytes; low white blood cell count; cardiac failure; pneumonia; respiratory tract infection, urinary tract infection; peripheral neuropathy; back pain; muscle spasms; bone pain; fatigue.
The risk of vascular occlusive events (arterial and venous thrombosis and occlusions, including fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures) and heart failure have been reported with ponatinib.